[HTML][HTML] Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
…, N Kitchin, J Absalon, A Gurtman, S Lockhart, K Neuzil… - Nature, 2020 - nature.com
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19),
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
[HTML][HTML] Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
…, A Brosz, C Fierro, H Schwartz, K Neuzil… - New England journal …, 2021 - Mass Medical Soc
Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …
[HTML][HTML] Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19
…, MF Ryser, MA Marovich, KM Neuzil… - … England Journal of …, 2021 - Mass Medical Soc
Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …
[HTML][HTML] Durability of responses after SARS-CoV-2 mRNA-1273 vaccination
…, S O'Dell, SD Schmidt, KM Neuzil… - … England Journal of …, 2021 - Mass Medical Soc
Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two
100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein …
100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein …
[HTML][HTML] An mRNA vaccine against SARS-CoV-2—preliminary report
…, M Padilla, JR Mascola, KM Neuzil… - New England journal …, 2020 - Mass Medical Soc
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged
in late 2019 and spread globally, prompting an international effort to accelerate development …
in late 2019 and spread globally, prompting an international effort to accelerate development …
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
…, MP Andrasik, JG Kublin, L Corey, KM Neuzil… - Science, 2022 - science.org
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …
[HTML][HTML] Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
…, S Sproule, ML Robb, L Corey, KM Neuzil… - … England Journal of …, 2021 - Mass Medical Soc
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…
[HTML][HTML] Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
…, A Gurtman, S Lockhart, K Neuzil… - … England Journal of …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
[HTML][HTML] Homologous and heterologous Covid-19 booster vaccinations
…, DC Montefiori, A Eaton, KM Neuzil… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …
have received emergency use authorization in the United States are highly effective, …
[HTML][HTML] Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
…, L Han-Conrad, M Levin, KM Neuzil… - … England Journal of …, 2021 - Mass Medical Soc
Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …